Field notes from the interior
What the evidence actually supports, written without the enthusiasm tax.
What the scale hides: lean mass in GLP-1 weight loss
Between a quarter and nearly half of the weight lost on GLP-1 therapy is lean tissue, and the proportion differs by drug. That ratio is not fixed, and only two interventions reliably move it.
Resistance training is the intervention, not the accessory
Of everything bolted onto a GLP-1 programme, loading the muscle has the clearest evidence behind it, and the lowest adoption.
Fiber has a ceiling, and a slowed gut lowers it
More is better right up until it isn't. On a GLP-1, the point where fiber stops helping arrives earlier than most guidance accounts for.
What a real baseline panel actually screens for
Six tests, each answering a specific question about whether treatment is safe and what it should be aiming at. None of them are exotic.
"Research use only" is a confession, not a disclaimer
The grey market in GLP-1s and peptides competes on price by removing every control that makes an injectable safe. The label tells you so.
The trial record, without the enthusiasm tax
STEP, SURMOUNT, SELECT, FLOW. What each one actually established, in whom, and (the part usually left out) what none of them establish.
The escape velocity claim, and the one paper that argues back
Kurzweil, de Grey, Sinclair and Diamandis have each put a date on outrunning aging. One peer-reviewed analysis says this century will not deliver it. The asymmetry between those two kinds of statement is the story.